MVM Life Science Partners, Apposite Capital and Novo co-led an initial £10.3m first round of funding in the company in July 2007. US venture firm East Hill, which became a shareholder in Serentis following the acquisition of Surface Therapeutics in 2007, also participated in the financing. Serentis is developing a pipeline of products for the treatment of various dermatological conditions. “Since our initial financing a year ago, Serentis has made significant progress in identifying and developing our pipeline,” says Serentis CEO and co-founder Tim Sharpington. “These funds will enable us to move our lead products towards key clinical milestones and to identify additional targets.” Picture source
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.